Table 4.
ID | min # of 454 reads | NVP resistance mutations detected by UDPS1
|
NRTI2
|
total % reistance | # of sites with NVP resistance3 | # of sites NVP + NRTI resistance3 | months of follow-up | time of VF | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
K101
|
K103
|
V106
|
Y181
|
G190
|
F227
|
M184
|
||||||||||||
E | N | S | T | A | M | C | A | E | T | C | 1 | |||||||
7 | 11134 | 0.21% | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | 0.21% | 1 | 1 | 21 | month 6 |
9 | 8598 | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | 0.13% | 0.13%* | 0 | 1 | 6 | month 3 |
11 | 12999 | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | 0.07% | bd | 0.07% | 1 | 1 | 21 | month 21 |
17 | 11029 | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | 0.23% | 0.23%* | 0 | 1 | 3 | month 3 |
19 | 6203 | 0.20% | bd | bd | bd | bd | bd | bd | 3.76% | bd | bd | bd | bd | 3.96% | 2 | 2 | 3 | month 3 |
22 | 9529 | bd | 49.90% | bd | 0.32% | bd | bd | 0.49% | 0.34% | bd | bd | bd | bd | 51.05% | 3 | 3 | 12 | month 6 |
24 | 4212 | bd | 10.62% | bd | 0.80% | 9.97% | 0.19% | bd | 0.65% | bd | bd | bd | bd | 22.24% | 3 | 3 | 12 | month 9 |
2 | 5374 | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | 0% | 0 | 0 | 24 | int |
3 | 15058 | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | 0% | 0 | 0 | 12 | nf |
4 | 14402 | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | 0% | 0 | 0 | 6 | nf |
8 | 10382 | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | 0% | 0 | 0 | 21 | nf |
12 | 14318 | bd | 99.83% | 0.18% | bd | bd | bd | bd | bd | bd | bd | bd | bd | 100.01% | 1 | 1 | 3 | nf |
14 | 4497 | bd | bd | bd | bd | bd | bd | bd | 99.95% | bd | 0.06% | bd | bd | 100.01% | 1 | 1 | 3 | nf |
15 | 13633 | bd | 99.71% | 0.13% | bd | bd | bd | bd | bd | bd | bd | bd | bd | 99.83% | 1 | 1 | 3 | nf |
18 | 15305 | bd | bd | bd | bd | bd | bd | bd | bd | 0.64% | bd | bd | bd | 0.64% | 1 | 1 | 12 | nf |
20 | 14478 | bd | 0.18% | bd | bd | bd | bd | 0.36% | bd | bd | bd | bd | bd | 0.54% | 2 | 2 | 3 | nf |
28 | 13964 | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | 0% | 0 | 0 | 3 | nf |
29 | 4923 | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | 0% | 0 | 0 | 9 | nf |
30 | 7783 | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | 0% | 0 | 0 | 6 | nf |
32 | 13646 | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | bd | 0% | 0 | 0 | 3 | nf |
bd = below detection, VF = viral failure, int = intermittent viremia, nf = no failure
NVP resistance mutations assayed by UDPS with no detectable resistance in any samples are not included in the table: L100I, K101P, V179F, Y181I/S/V, Y188C/H/L, G190C/Q/S/V
NRTI resistance mutations assayed by UDPS with no detectable resistance in any samples are not included in table: Q151M, M184V, T215F/Y
Changes to different amino acids at the same position were counted as a single site of resistance
For these cases, resistance would be 0% if NRTI sites were excluded.